Zhongfang Wang

Guangzhou Medical University - State Key Laboratory of Respiratory Disease

Guangzhou, Guangdong

China

SCHOLARLY PAPERS

4

DOWNLOADS

328

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (4)

1.

Safety, Immunogenicity and Efficacy of the mRNA Vaccine CS-2034 as a Heterologous Booster Versus Homologous Booster with BBIBP-CorV in Adults Aged ≥18 Years: A Randomized, Partial-Blind, Phase 2b Trial

Number of pages: 25 Posted: 15 Feb 2023
Yixing People's Hospital, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., Yixing People's Hospital, Yixing People's Hospital, CanSino Biologics Inc., Yixing People's Hospital, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Laboratory, CanSino Biologics Inc., CanSino Biologics Inc., CanSino Biologics Inc., Guangzhou Medical University - State Key Laboratory of Respiratory Disease and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology
Downloads 192 (297,352)

Abstract:

Loading...

SARS-CoV-2, Omicron, heterologous booster, homologous booster, mRNA vaccine CS-2034, safety, immunogenicity

2.

Safety and Immunogenicity of Heterologous and Homologous Boosting with Orally Aerosolized or Intramuscular Ad5-nCoV and Inactivated Vaccines in Children and Adolescents: A Randomized, Open-Label, Parallel Controlled, Single-Center Study

Number of pages: 20 Posted: 20 Dec 2022
Hunan Provincial Center for Disease Control and Prevention, Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, Hunan Provincial Center for Disease Control and Prevention, Academy of Military Medical Sciences - Institute of Biotechnology, Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, CanSino Biologics Inc., Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Hunan Provincial Center for Disease Control and Prevention, Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, Academy of Military Medical Sciences - Institute of Biotechnology, CanSino Biologics Inc., Government of the People's Republic of China - Beijing Key Laboratory of Pediatric Organ Failure, Beijing Institute of Biotechnology, CanSino Biologics Inc., CanSino Biologics Inc., Academy of Military Medical Sciences - Institute of Biotechnology, Hunan Provincial Center for Disease Control and Prevention and Southern Medical University - Neonatal Intensive Care Unit
Downloads 87 (546,800)

Abstract:

Loading...

COVID-19 vaccine, mucosal vaccine, children, adolescents, clinical trial

3.

Safety, Tolerability, and Immunogenicity of a CpG/Alum Adjuvanted SARS-CoV-2 Recombinant Protein Vaccine (ZR202-CoV) in Healthy Adults: Preliminary Report of a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Number of pages: 21 Posted: 06 Mar 2023
Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Government of the People's Republic of China - National Institutes for Food and Drug Control, Henan Provincial Center for Disease Control Prevention, Shanghai Zerun Biotechnology Co. LTD., Tsinghua University, Tsinghua University, National Institute for Food and Drug Control, Guangzhou Medical University - Guangzhou Institute of Respiratory Health, Henan Provincial Center for Disease Control Prevention, Xiangcheng County Center for Disease Control and Prevention, Beijing Key Tech Statistics Technology Co., Ltd., Shanghai Zerun Biotechnology Co. LTD., Shanghai Zerun Biotechnology Co. LTD., Shanghai Zerun Biotechnology Co. LTD., Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Walvax Biotechnology Co Ltd, Walvax Biotechnology Co Ltd, Shanghai Zerun Biotechnology Co. LTD., Walvax Biotechnology Co Ltd, Henan Provincial Center for Disease Control Prevention, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Government of the People's Republic of China - National Institutes for Food and Drug Control and Shanghai Zerun Biotechnology Co. LTD.
Downloads 39 (804,504)

Abstract:

Loading...

COVID-19, SARS-CoV-2 vaccine, Safety, Immunogenicity, Placebo-controlled, Clinical trial

4.

The Establishment of a CMV-Specific CD8 + T-Cell Threshold by Kinetic Modelling for Prediction of Post-HSCT Reactivation

Number of pages: 70 Posted: 10 Jan 2022
Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, Guangzhou Medical University - Department of Hematology, Guangzhou Medical University, Guangzhou Medical University - State Key Laboratory of Respiratory Disease, South China University of Technology - Department of Hematology, University of Melbourne - Department of Microbiology and Immunology (DMI), Guangzhou Medical University - State Key Laboratory of Respiratory Disease, University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - Department of Microbiology and Immunology (DMI), University of Melbourne - School of Mathematics and Statistics, South China University of Technology - Department of Hematology and Guangzhou Medical University - State Key Laboratory of Respiratory Disease
Downloads 10 (1,077,080)

Abstract:

Loading...

CMV reactivation, allo-HSCT, CD8+ T cell, threshold, antiviral therapy